Graham Cooper Board Member
Graham Cooper is a member of the boards of directors of other public companies including Unity Biotechnology and Kezar Life Sciences.
Mr. Cooper is focused on financial operations and capital markets strategy. He was previously the chief financial officer and chief operating officer of Assembly Biosciences, a biotechnology company developing therapeutics targeting hepatitis B virus. Prior to joining Assembly, he was chief financial officer of Receptos, from 2013 until its sale in 2015 to Celgene.
Previously, Mr. Cooper was the chief financial officer of Geron Corporation, and from 2006 until 2011, served as chief financial officer of Orexigen Therapeutics. From 1999 to 2006, Mr. Cooper held positions of increasing responsibility including director of healthcare investment banking at Deutsche Bank Securities, where he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field. From 1992 to 1995, he worked as an accountant at Deloitte & Touche, where he earned his C.P.A. (currently inactive).
Mr. Cooper holds a B.A. in economics from the University of California at Berkeley and an MBA from the Stanford Graduate School of Business.